Affective state determination in a mouse model of colitis-associated colorectal cancer

PLoS One. 2020 Jan 27;15(1):e0228413. doi: 10.1371/journal.pone.0228413. eCollection 2020.

Abstract

Behavioural indicators of affective state, including burrowing, clinical scores and the Mouse Grimace Score have not yet been validated in mouse models of chronic gastrointestinal disease. Additionally, a comparison of these methods has not been characterised. This study aimed to determine which behavioural assessment was the optimal indicator of disease, evidenced by correlation with clinically-assessed measures, in an azoxymethane (AOM)/dextran sulphate sodium (DSS) mouse model of colitis-associated colorectal cancer. C57BL/6 mice were allocated to four groups (n = 10/group); 1) saline control, 2) saline+buprenorphine, 3) AOM+DSS+water, 4) AOM+DSS+buprenorphine. Mice were gavaged thrice weekly with water or buprenorphine (0.5mg/kg; 80μL) for 9 weeks. Disease activity index (DAI) was measured daily; burrowing and grimace analyses occurred on days -1, 5, 19, 26, 40, 47 and 61. Colonoscopies were performed on days 20, 41 and 62. All animals were euthanized on day 63. Burrowing activity and retrospective grimace analyses were unaffected (P>0.05), whilst DAI was significantly increased (P<0.05) in mice with colitis-associated colorectal cancer compared to normal controls. In addition, DAI was positively correlated with colonoscopically-assessed severity and tumour number (P<0.05). We conclude that traditional measures of DAI or clinical scoring provide the most reliable assessment of wellbeing in mice with colitis-associated colorectal cancer.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azoxymethane / adverse effects*
  • Behavior
  • Buprenorphine / administration & dosage*
  • Colitis / chemically induced
  • Colitis / complications*
  • Colonoscopy
  • Colorectal Neoplasms / complications*
  • Colorectal Neoplasms / etiology
  • Colorectal Neoplasms / psychology
  • Dextran Sulfate / adverse effects*
  • Disease Models, Animal
  • Mice
  • Mice, Inbred C57BL
  • Pain Measurement / methods*
  • Retrospective Studies
  • Risk Assessment

Substances

  • Buprenorphine
  • Dextran Sulfate
  • Azoxymethane

Grants and funding

LCC received partial funding from The Australian Veterinary Association for the current study (Animal Welfare Trust Grant; www.ava.com.au). LCC is also supported by an Australian Government Research Training Program Stipend and a PhD Top-Up Scholarship from AgriFutures Australia (www.agrifutures.com.au). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.